Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer.
Ribociclib Plus Endocrine Therapy Reduces Disease Progression in HR+/HR- Advanced Breast Cancer
Ribociclib showed a significant reduction in risk of disease progression in patients with pre- and perimenopausal HR+, HR- advanced breast cancer.
Investigators Identify Immunotherapy Followed by BRAK/MEK Inhibition as Optimal Sequence Strategy in BRAF+ Melanoma
Optimal treatment sequencing for patients with BRAF-mutated melanoma involves frontline immunotherapy following by BRAF/MEK inhibition, according to investigators.
Ivosidenib/Azacitidine Combination Achieves Favorable Responses in IDH1-Mutant AML
At a median follow-up of 12.4 months, patients with IDH1-mutated acute myeloid leukemia had achieved a significant improvement in event-free survival with ivosidenib/azacitidine compared with placebo.
Darolutamide Extends Survival in nmCRPC Regardless of Prior RT or Radical Prostatectomy
Darolutamide significantly prolonged metastasis-free survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer with no added toxicity.
Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related Parameters
Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.
Advancements in cGVHD Yield New and Anticipated Treatment Options
Chronic graft-versus-host disease management has continued to advance in recent years, with new and anticipated treatment options for its treatment landscape.
There’s No Place Like Home: The Launch of In-Home Infusion Programs
Ruxolitinib Is Promising in Pediatric Chronic GVHD
Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.
Azacitidine Improves Survival Outcomes, Quality of Life in AML
Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.
Examining Racial Genomics in Prostate Cancer
Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
ctDNA Identifies Adjuvant MRD Positivity, Relapse in Lung Cancer
In the adjuvant setting, circulating tumor DNA (ctDNA) may be a biomarker for the detection of post-surgical minimal residual disease (MRD) and for determining the clonality of relapsing disease.
Expert Discusses Individualized Care for GI Cancers
While earlier efforts of precision medicine focused on basket trials, Tanios S. Bekaii-Saab, MD, explained that it’s time for the field of oncology to move on to umbrella trial designs that can better target an individual cancer.
Moving Towards Precision Medicine in MCL
Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512